AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out?

Company Performance - AtriCure's shares have increased by 2.4% over the past month, reaching a new 52-week high of $43.18, with a year-to-date gain of 7.2% compared to the Zacks Medical sector's 7.8% and the Zacks Medical - Products industry's -0.5% return [1] - The company has consistently exceeded earnings expectations, reporting an EPS of -$0.01 against a consensus estimate of -$0.11 in its last earnings report on October 29, 2025, and beating revenue estimates by 2.09% [2] Future Earnings Projections - For the current fiscal year, AtriCure is projected to have earnings of -$0.08 per share on revenues of $533.17 million, while for the next fiscal year, earnings are expected to rise to $0.34 per share on revenues of $599.85 million, indicating year-over-year changes of 63.54% and 12.51%, respectively [3] Valuation Metrics - AtriCure has a Value Score of C, a Growth Score of A, and a Momentum Score of C, resulting in a VGM Score of B, which suggests a balanced investment profile [6] - The stock currently holds a Zacks Rank of 2 (Buy), indicating rising earnings estimates and meeting the criteria for potential investment [7] Industry Comparison - AtriCure's performance is favorable compared to its industry peers, such as VAREX IMAGING, which also has a Zacks Rank of 2 (Buy) and strong earnings performance, having beaten consensus estimates by 105.56% last quarter [8][9] - Despite the Medical - Products industry ranking in the bottom 67% of all industries, AtriCure and VAREX IMAGING are positioned to benefit from favorable market conditions [10]